Stacey Associates buys Gilead shares; other funds add stakes, insider sells
Stacey Associates acquired 102,562 shares of Gilead Sciences for about $12.96 million, and other investors added smaller positions, including a new stake for Kimelman & Baird and additional purchases by Vermillion & White. An insider, Johanna Mercier, sold 28,000 shares for $2.68 million. Analysts’ targets were adjusted, with Barclays lowering its target and Royal Bank of Canada raising its.